A family of neutral serine proteases with CHYMOTRYPSIN-like activity. Chymases are primarily found in the SECRETORY GRANULES of MAST CELLS and are released during mast cell degranulation.
A family of neutral serine proteases with TRYPSIN-like activity. Tryptases are primarily found in the SECRETORY GRANULES of MAST CELLS and are released during mast cell degranulation.
Any member of the group of ENDOPEPTIDASES containing at the active site a serine residue involved in catalysis.
Granulated cells that are found in almost all tissues, most abundantly in the skin and the gastrointestinal tract. Like the BASOPHILS, mast cells contain large amounts of HISTAMINE and HEPARIN. Unlike basophils, mast cells normally remain in the tissues and do not circulate in the blood. Mast cells, derived from the bone marrow stem cells, are regulated by the STEM CELL FACTOR.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.

Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery. (1/553)

BACKGROUND: Activation of vascular chymase plays a major role in myointimal hypertrophy after vascular injury by augmenting the production of angiotensin (ANG) II. Because chymase is synthesized mainly in mast cells, we assumed that the chymase-dependent ANG II formation could be downregulated by tranilast, a mast cell-stabilizing antiallergic agent. We have assessed inhibitory effects of tranilast on neointima formation after balloon injury in the carotid artery of dogs, which share a similar ANG II-forming chymase with humans, and further explored the pathophysiological significance of vascular chymase. METHODS AND RESULTS: Either tranilast (50 mg/kg BID) or vehicle was orally administered to beagles for 2 weeks before and 4 weeks after balloon injury. Four weeks after the injury, remarkable neointima was formed in the carotid arteries of vehicle-treated dogs. Chymase mRNA levels and chymaselike activity of vehicle-treated injured arteries were increased 10.2- and 4.8-fold, respectively, those of uninjured arteries. Angiotensin-converting enzyme (ACE) activity was slightly increased in the injured arteries, whereas ACE mRNA levels were not. Tranilast treatment completely prevented the increase in chymaselike activity, reduced the chymase mRNA levels by 43%, and decreased the carotid intima/media ratio by 63%. In vehicle-treated injured arteries, mast cell count in the adventitia showed a great increase, which was completely prevented by the tranilast treatment. Vascular ACE activity and mRNA levels were unaffected by tranilast. CONCLUSIONS: Tranilast suppressed chymase gene expression, which was specifically activated in the injured arteries, and prevented neointima formation. Suppression of the chymase-dependent ANG II-forming pathway may contribute to the beneficial effects of tranilast.  (+info)

Lack of effect of carbohydrate depletion on some properties of human mast cell chymase. (2/553)

Human chymase from vascular tissues was purified to homogeneity by heparin affinity and gel filtration chromatography. Treatment of human chymase with endoglycosidase F resulted in cleavage of the carbohydrate moiety yielding a deglycosylation product that did not lose its catalytic activity. This enzymatic deglycosylation product was enough to explore possibilities that N-glycan might modify some properties of human chymase. Substrate specificity, optimum pH and the elution profile from the heparin affinity gel were not affected by the deglycosylation. Only a slight but significant difference was observed in the Km value for conversion of angiotensin I to angiotensin II. Other kinetic constants such as kcat were not influenced. The kinetics of conversion of big endothelin-1 to endothelin-1(1-31) were not significantly affected. The deglycosylated human chymase was more susceptible to deactivation under alkaline pH and thermal stress. Even at physiological temperature and pH, the activity of glycosylated human chymase was more stable. From these results, it appears that the N-glycan of human chymase contributes to the stability of this enzyme but not to its functional properties.  (+info)

Induction of atherosclerosis in Brown Norway rats by immunization with ovalbumin. (3/553)

A study was carried out to establish an animal model that would be suitable for evaluating the role of the diet in immune cell-mediated atherogenesis. Brown Norway rats were initially treated with hypervitamin D2 for 4 days and then fed on an atherogenic diet for 3 months, during which period the rats were either immunized with ovalubumin plus Al(OH)3 (OVA group) or with Al(OH)3 alone (control group) every 3 weeks. Aortic lesions were mainly composed of foam cells, the lesions evaluated by the intimal thickness of the ascending aorta being more severe in the OVA group than in the control group. The OVA group, in comparison with the control group, showed prominently increased serum levels of OVA-specific IgG and rat chymase, an indicator of mast cell degranulation. The intimal thickness was positively correlated with the level of chymase. Immunization had no effect on the serum lipid levels. These results support the hypothesis that mast cells play a role in the early stage of atherosclerosis and suggest that this animal model could be useful for evaluating the role of the diet in immune-related atherogenesis.  (+info)

Fibroproliferation and mast cells in the acute respiratory distress syndrome. (4/553)

BACKGROUND: Mast cells (MCs), which are a major source of cytokines and growth factors, have been implicated in various fibrotic disorders. To clarify the contribution of MCs to fibrogenesis, lung tissue from patients with the acute respiratory distress syndrome (ARDS) was examined during exudative through to fibroproliferative stages. METHODS: Lung tissue was obtained from 17 patients with ARDS who had pathological features of the early exudative stage (n = 6) or the later reparative stages (n = 11), from four patients with idiopathic pulmonary fibrosis, and from three patients with normal lung tissue. Immunohistochemical localisation of tryptase (found in all human MCs), chymase (found in a subset of human MCs), alpha-smooth muscle actin (identifies myofibroblasts), and procollagen type I was performed. RESULTS: Normal lung tissue exhibited myofibroblast and procollagen type I immunolocalisation scores each of < 5 and MC scores of 1. Increased scores were defined as myofibroblast and procollagen type I scores of > 10 and MC scores of > or = 2. Eighty percent of lung tissue samples from the early exudative stage of ARDS exhibited increased numbers of myofibroblasts, 50% had increased numbers of procollagen type I producing cells, while only 17% had increased numbers of MCs compared with control samples. All samples from the later reparative stages of ARDS had increased numbers of myofibroblasts and procollagen type I producing cells. Increased numbers of MCs were seen in 55% of samples from the reparative stages. There was no significant shift in MC phenotype in the ARDS samples. CONCLUSIONS: Increased numbers of myofibroblasts and procollagen type I producing cells were frequently found early in the course of ARDS. MC hyperplasia was unusual during this stage, but was often a feature of the later reparative stages. MCs do not appear to initiate fibroproliferation in ARDS.  (+info)

Depletion of pre beta 1LpA1 and LpA4 particles by mast cell chymase reduces cholesterol efflux from macrophage foam cells induced by plasma. (5/553)

Exposure of the LpA1-containing particles present in HDL3 and plasma to a minimal degree of proteolysis by the neutral protease chymase from exocytosed rat mast cell granules (granule remnants) leads to a reduction in the high-affinity component of cholesterol efflux from macrophage foam cells. In this study, we demonstrate for the first time, a role for mast cell chymase in the depletion of the lipid-poor minor components of HDL that are specifically involved in reverse cholesterol transport as initial acceptors of cellular cholesterol. Thus, addition of proteolytically active granule remnants or human skin chymase to cholesterol-loaded macrophages of mouse or human origin incubated with human apoA1, ie, a system in which prebeta1LpA1 is generated, resulted in a sharp reduction in the high-affinity cholesterol efflux promoted by apoA1. As determined by nondenaturing 2-dimensional polyacrylamide gradient gel electrophoresis, the granule remnants effectively depleted the prebeta1LpA1, but not the alphaLpA1, in HDL3 and in plasma during incubation at 37 degrees C for <1 hour. Incubation of plasma with granule remnants for 1 hour also led to near disappearance of the LpA4-1 and LpA4-2 particles, but did not affect the distribution of the apoA2-containing lipoproteins present in the plasma. We conclude that the reduced ability of granule remnant-treated HDL3 and granule remnant-treated plasma to induce cholesterol efflux from macrophage foam cells is caused by selective depletion by mast cell chymase of quantitatively minor A1- and A4-containing subpopulations of HDL. Because these particles, ie, prebeta1LpA1 and LpA4, are efficient acceptors of cholesterol from cell surfaces, their depletion by mast cells may block the initiation of reverse cholesterol transport in vivo and thereby favor foam cell formation in the arterial intima, the site of atherogenesis.  (+info)

Mast cell expression of gelatinases A and B is regulated by kit ligand and TGF-beta. (6/553)

Our prior work shows that cultured BR cells derived from dog mastocytomas secrete the 92-kDa proenzyme form of gelatinase B. We provided a possible link between mast cell activation and metalloproteinase-mediated matrix degradation by demonstrating that alpha-chymase, a serine protease released from secretory granules by degranulating mast cells, converts progelatinase B to an enzymatically active form. The current work shows that these cells also secrete gelatinase A. Furthermore, gelatinases A and B both colocalize to alpha-chymase-expressing cells of canine airway, suggesting that normal mast cells are a source of gelatinases in the lung. In BR cells, gelatinase B and alpha-chymase expression are regulated, whereas gelatinase A expression is constitutive. Progelatinase B mRNA and enzyme expression are strongly induced by the critical mast cell growth factor, kit ligand, which is produced by fibroblasts and other stromal cells. Induction of progelatinase B is blocked by U-73122, Ro31-8220, and thapsigargin, implicating phospholipase C, protein kinase C, and Ca2+, respectively, in the kit ligand effect. The profibrotic cytokine TGF-beta virtually abolishes the gelatinase B mRNA signal and also attenuates kit ligand-mediated induction of gelatinase B expression, suggesting that an excess of TGF-beta in inflamed or injured tissues may alter mast cell expression of gelatinase B, which is implicated in extracellular matrix degradation, angiogenesis, and apoptosis. In summary, these data provide the first evidence that normal mast cells express gelatinases A and B and suggest pathways by which their regulated expression by mast cells can influence matrix remodeling and fibrosis.  (+info)

A novel function for transforming growth factor-beta1: upregulation of the expression and the IgE-independent extracellular release of a mucosal mast cell granule-specific beta-chymase, mouse mast cell protease-1. (7/553)

Intestinal mucosal mast cells (IMMC) express granule neutral proteases that are regulated by T-cell-derived cytokines, including interleukin-3 (IL-3) and IL-9, and by stem cell factor (SCF). The IMMC-specific chymase, mouse mast cell protease-1 (mMCP-1), is released in substantial quantities into the blood stream during gastrointestinal allergic responses. We used cultured bone marrow-derived mast cells (mBMMC) to identify cytokines that regulate the expression and extracellular release of mMCP-1. When grown in IL-3-rich WEHI (15% vol/vol) and 50 ng/mL recombinant rat SCF (rrSCF) bone marrow cells supplemented with IL-9 (5 ng/mL) differentiated into mBMMC that expressed a maximum of less than 250 ng mMCP-1/10(6) cells and 189 ng mMCP-1/mL of culture supernatant. Supplementation of the same three cytokines with transforming growth factor-beta1 (TGF-beta1; 1 ng/mL) resulted in substantially enhanced expression (6 micrograms/10(6) mBMMC) and extracellular release (2 micrograms/mL of culture supernatant) of mMCP-1. The response to TGF-beta1 was dose-dependent, with maximal effect at 1 ng/mL, and was associated with immunohistochemical and ultrastructural changes in the secretory granules. IL-9-induced expression of mMCP-1 may be due to endogenously expressed TGF-beta1, because it was blocked by anti-TGF-beta antibodies. In conclusion, the expression and extracellular release of the IMMC-specific chymase, mMCP-1, is strictly regulated by TGF-beta1.  (+info)

Evidence for angiotensin-converting enzyme- and chymase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo. (8/553)

BACKGROUND: We have previously demonstrated that angiotensin II (Ang II) levels in the interstitial fluid (ISF) space of the heart are higher than in the blood plasma and do not change after systemic infusion of Ang I. In this study, we assess the enzymatic mechanisms (chymase versus ACE) by which Ang II is generated in the ISF space of the dog heart in vivo. METHODS AND RESULTS: Cardiac microdialysis probes were implanted in the left ventricular (LV) myocardium (3 to 4 probes per dog) of 12 anesthetized open-chest normal dogs. ISF Ang I and II levels were measured at baseline and during ISF infusion of Ang I (15 micromol/L, n=12), Ang I+the ACE inhibitor captopril (cap) (2.5 mmol/L, n=4), Ang I+the chymase inhibitor chymostatin (chy) (1 mmol/L, n=4), and Ang I+cap+chy (n=4). ISF infusion of Ang I increased ISF Ang II levels 100-fold (P<0.01), whereas aortic and coronary sinus plasma Ang I and II levels were unaffected and were 100-fold lower than ISF levels. Compared with ISF infusion of Ang I alone, Ang I+cap (n=4) produced a greater reduction in ISF Ang II levels than did Ang I+chy (n=4) (71% versus 43%, P<0.01), whereas Ang I+cap+chy produced a 100% decrease in ISF Ang II levels. CONCLUSIONS: This study demonstrates for the first time a very high capacity for conversion of Ang I to Ang II mediated by both ACE and chymase in the ISF space of the dog heart in vivo.  (+info)

Chymases are a type of enzyme that belong to the family of serine proteases. They are found in various tissues and organs, including the heart, lungs, and immune cells called mast cells. Chymases play a role in several physiological and pathological processes, such as inflammation, tissue remodeling, and blood pressure regulation.

One of the most well-known chymases is found in the mast cells and is often referred to as "mast cell chymase." This enzyme can cleave and activate various proteins, including angiotensin I to angiotensin II, a potent vasoconstrictor that increases blood pressure. Chymases have also been implicated in the development of cardiovascular diseases, such as hypertension and heart failure, as well as respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD).

In summary, chymases are a group of serine protease enzymes that play important roles in various physiological and pathological processes, particularly in inflammation, tissue remodeling, and blood pressure regulation.

Tryptase is a type of enzyme that is found in the cells called mast cells, which are a part of the immune system. Specifically, tryptase is a serine protease, which means it helps to break down other proteins in the body. Tryptase is often released during an allergic reaction or as part of an inflammatory response. It can be measured in the blood and is sometimes used as a marker for mast cell activation or degranulation. High levels of tryptase may indicate the presence of certain medical conditions, such as systemic mastocytosis or anaphylaxis.

Serine endopeptidases are a type of enzymes that cleave peptide bonds within proteins (endopeptidases) and utilize serine as the nucleophilic amino acid in their active site for catalysis. These enzymes play crucial roles in various biological processes, including digestion, blood coagulation, and programmed cell death (apoptosis). Examples of serine endopeptidases include trypsin, chymotrypsin, thrombin, and elastase.

Mast cells are a type of white blood cell that are found in connective tissues throughout the body, including the skin, respiratory tract, and gastrointestinal tract. They play an important role in the immune system and help to defend the body against pathogens by releasing chemicals such as histamine, heparin, and leukotrienes, which help to attract other immune cells to the site of infection or injury. Mast cells also play a role in allergic reactions, as they release histamine and other chemicals in response to exposure to an allergen, leading to symptoms such as itching, swelling, and redness. They are derived from hematopoietic stem cells in the bone marrow and mature in the tissues where they reside.

An amino acid sequence is the specific order of amino acids in a protein or peptide molecule, formed by the linking of the amino group (-NH2) of one amino acid to the carboxyl group (-COOH) of another amino acid through a peptide bond. The sequence is determined by the genetic code and is unique to each type of protein or peptide. It plays a crucial role in determining the three-dimensional structure and function of proteins.

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

For example, chymases are released by connective tissue-type mast cells upon challenge with parasites and parasite antigens ... Chymases (EC 3.4.21.39, mast cell protease 1, skeletal muscle protease, skin chymotryptic proteinase, mast cell serine ... May 2005). "A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti- ... Caughey GH (June 2007). "Mast cell tryptases and chymases in inflammation and host defense". Immunological Reviews. 217: 141-54 ...
"Entrez Gene: CMA1 chymase 1, mast cell". Urata H, Nishimura H, Ganten D (1996). "Chymase-dependent angiotensin II forming ... Chymase is an enzyme that in humans is encoded by the CMA1 gene. This gene product is a chymotryptic serine proteinase that ... 1991). "Cloning of the gene and cDNA for human heart chymase". J. Biol. Chem. 266 (26): 17173-9. doi:10.1016/S0021-9258(19) ... Jenne DE, Tschopp J (1991). "Angiotensin II-forming heart chymase is a mast-cell-specific enzyme". Biochem. J. 276 (2): 567-8. ...
Caughey GH (June 2007). "Mast cell tryptases and chymases in inflammation and host defense". Immunological Reviews. 217 (1): ...
One counterexample is the protein chymase, which directly binds to heparin. Dermatan sulfate is one example of a compound that ...
Mellon MB, Frank BT, Fang KC (2002). "Mast cell alpha-chymase reduces IgE recognition of birch pollen profilin by cleaving ...
... functions together with endopeptidases secreted from mast cells such as chymases and tryptases to degrade proteins and ... Sequential degradation of apolipoprotein B by granule chymase and carboxypeptidase A". The Journal of Biological Chemistry. 261 ... the chymases, and tryptases are released in complexes with heparin proteoglycan. The parasitic nematode Ascaris produces CPA3 ... "Cooperation between mast cell carboxypeptidase A and the chymase mouse mast cell protease 4 in the formation and degradation of ...
... inhibits human leukocyte elastase, human cathepsin G, human trypsin, neutrophil elastase, and mast cell chymase. X-ray ...
... and heterogeneity of mast cells with particular regard to the mast cell-specific proteases chymase and tryptase". Journal of ...
1999). "Tryptase-chymase double-positive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3-binding ... 1995). "Quantitation of tryptase, chymase, Fc epsilon RI alpha, and Fc epsilon RI gamma mRNAs in human mast cells and basophils ... 1997). "Effect of recombinant human IL-4 on tryptase, chymase, and Fc epsilon receptor type I expression in recombinant human ...
... cell carcinoma antigen 2 is a novel serpin that inhibits the chymotrypsin-like proteinases cathepsin G and mast cell chymase". ...
"Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from ...
... chymase or other enzymes can transform it into angiotensin II. This process can be intracellular or interstitial. In the ...
Wang ZM, Rubin H, Schechter NM (Nov 1995). "Production of active recombinant human chymase from a construct containing the ...
2002). "Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular ...
... and chymases found in mast cells, by cleaving them into a different shape or conformation. This activity protects some tissues ...
... chymase) activity and is taken up into cytoplasmic vesicles reminiscent of granzyme B-containing endosomes". J. Biol. Chem. 274 ...
... including the serine protease chymase. The activity of local renin-angiotensin systems and alternative pathways of angiotensin ...
... chymase, vasoactive intestinal peptide (VIP), vascular endothelial growth factor (VEGF), TNF, prostaglandins, leukotrienes, and ...
... such as elastase and cathepsin G in neutrophils cells and chymase and tryptase in mast cells. In many inflammatory diseases, ...
... enzyme also known as chymase MCP (disambiguation) This disambiguation page lists articles associated with the same title formed ...
... chymase, vasoactive intestinal peptide (VIP), vascular endothelial growth factor (VEGF), TNF, prostaglandins, leukotrienes, and ... such as tryptase and chymase histamine (2-5 picograms per mast cell) serotonin proteoglycans, mainly heparin (active as ...
... chymase EC 3.4.21.40: Deleted EC 3.4.21.41: Complement subcomponent C1r EC 3.4.21.42: complement subcomponent C1s EC 3.4.21.43 ...
... such as chymase. In cyclophosamide (CYP)-induced rodent models of interstitial cystitis/bladder pain syndrome (IC/PBS), CYP ...
... encoding enzyme Chymase CNIH: encoding protein Protein cornichon homolog COCH: coagulation factor C homolog, cochlin (Limulus ...
... chymase, vasoactive intestinal peptide (VIP), vascular endothelial growth factor (VEGF), TNF, prostaglandins, leukotrienes, and ...
For example, chymases are released by connective tissue-type mast cells upon challenge with parasites and parasite antigens ... Chymases (EC 3.4.21.39, mast cell protease 1, skeletal muscle protease, skin chymotryptic proteinase, mast cell serine ... May 2005). "A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti- ... Caughey GH (June 2007). "Mast cell tryptases and chymases in inflammation and host defense". Immunological Reviews. 217: 141-54 ...
Storage Stability: -20°C/1 year Gene Name: CMA1 Protein Name: Chymase Human ... Chymase Polyclonal Antibody Catalog No.: ALT5123 Reactivity: Human;Rat;Mouse; Applications: WB;ELISA Source: Polyclonal, Rabbit ... Other Name: CMA1; CYH; CYM; Chymase; Alpha-chymase; Mast cell protease I ... Western Blot analysis of mouse lung cells using Chymase Polyclonal Antibody. Secondary antibody(catalog#:RS0002) was diluted at ...
hCA IX was the most inhibited isoform ( em KI /em s ranging between 243.6 and 2658.3?nm) whereas hCA IV was not inhibited by these compounds. d, 8.4), 8.82 (1H, s, exchange with D2O, N(ESI negative) 358.0 [M???H]?. 2-Methyl-N-((2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)carbamoyl)benzenesulfonamide (4) White solid, yield 79%, m.p.: 285C286?C; silica gel TLC 7.6), 2.66 (3H, s), 2.80 (2H, t, 7.6), 6.81 (1H, d, 8.0), 7.05 (2H, m), 7.47 (2H, m), 7.61 (1H, m), 8.01 (1H, d, 7.6), 8.69 (1H, s, exchange with D2O, N(ESI negative) 358.0 [M???H]?. 4-Chloro-N-((2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)carbamoyl)benzenesulfonamide (5) White 20(R)Ginsenoside Rg2 colored solid, yield 67%; m.p.: 253C254?C; silica gel TLC 6.8), 2.81 (2H, t, 6.8), 6.85 (1H, dd, 2.0, 8.4), 7.01 (1H, d, 2.0), 7.06 (1H, d, 8.4), 7.75 (2H, d, 8.8), 8.01 (2H, d, 8.8), 8.94 (1H, s, exchange with D2O, N(ESI negative) 378.0 [M???H]?. 4-Fluoro-N-((2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)carbamoyl)benzenesulfonamide (6) White solid, yield 68%; m.p.: ...
Chymase 1 Protein. Synthesized inE.coli ;Yeast. Protein Tag: His-SUMO. Purity: Greater than 90% as determined by SDS-PAGE. From ... Recombinant Dog CMA1 / Chymase 1 Protein. https://enquirebio.com/wp-content/uploads/2018/01/QP5843-Dog-CMA1-Chymase-1-1.jpg. ... Recombinant Dog CMA1 / Chymase 1 Protein. $ 728.00 - $ 2,468.00. Please Select Product Options Below To View The Catalog Number ... Be the first to review "Recombinant Dog CMA1 / Chymase 1 Protein" Cancel reply. Your email address will not be published. ...
Chymase: Chymase plays a role in mucous secretion; degradation of IL-4 and extracellular matrix; decrease T-cell adhesion to ...
Chymase Forte - Indu Drugs. Chymin Forte - Emar Health Care. Chymobel Forte - Blubell Pharma. Chymoral - Elder Pharmaceuticals ...
In this diabetic mouse model, liver metastasis of CT26 cells was suppressed by anti-AT treatment with a chymase inhibitor, a ... HT29 cells expressed AT-II type 1 receptor, chymase, and rennin, whereas CT26 cells did not express renin. Renin expression and ... An inhibitor of renin or chymase abrogated A-II production in both cells. Reduction of hepatic ATG production by knockdown ...
We identified metalloproteinase, chymase, and cathepsins as the main proteolytic actors. The analysis indicated increased ... We identified metalloproteinase, chymase, and cathepsins as the main proteolytic actors. The analysis indicated increased ... abundance of cleaved APOA1 peptides is likely a consequence of enzymatic degradation by metalloproteinases and chymase. ... abundance of cleaved APOA1 peptides is likely a consequence of enzymatic degradation by metalloproteinases and chymase. ...
Proteases identified in excess in AA and other aortic diseases include matrix metalloproteinases (MMPs), cathepsins, chymase ...
... chymase) activity and is taken up into cytoplasmic vesicles reminiscent of granzyme B-containing endosomes," Journal of ...
chymase 1 [Source:HGNC Symbol;Acc.... COG5. 10466. COG5. component of oligomeric golgi com.... ...
Admin team lead, Admin team member, Analysis team lead, Analysis team member, Data collection lead, Data collection member, Manuscript analysis team lead, Manuscript analysis team members: Mendelian randomization, Manuscript analysis team members: methods development, Manuscript analysis team members: phenome-wide association study, Manuscript analysis team members: principal component projection, gene prioritization, Project management lead, Scientific communication lead, Scientific communication member, Writing group lead, Writing group member, 23andMe, Adolescent brain and cognitive development study, Analysis group, Armenia_Covid-19hg, & 49 othersAssessment of the influence of clinical, functional, immunological and genetic factors on the severity of the course of coronavirus infection with SARS-CoV-2 and post-COVID syndrome, Avon Longitudinal Study of Parents and Children (ALSPAC), BelCovid, Biobanque Quebec COVID19, BioVU, Bonn Study of COVID-19 Genetics, CGEn HostSeq-Canadian COVID-19 ...
Strippel, C., Herrera-Rivero, M., Wendorff, M., Tietz, A. K., Degenhardt, F., Witten, A., Schroeter, C., Nelke, C., Golombeck, K. S., Madlener, M., Rüber, T., Ernst, L., Racz, A., Baumgartner, T., Widman, G., Doppler, K., Thaler, F., Siebenbrodt, K., Dik, A., Kerin, C., &30 mehrRäuber, S., Gallus, M., Kovac, S., Grauer, O. M., Grimm, A., Prüss, H., Wickel, J., Geis, C., Lewerenz, J., Goebels, N., Ringelstein, M., Menge, T., Tackenberg, B., Kellinghaus, C., Bien, C. G., Kraft, A., Zettl, U., Ismail, F. S., Ayzenberg, I., Markewitz, R., Wandinger, K. P., Leypoldt, F., Lieb, W., Baumgartner, A., Hoffmann, A., Leypoldt, F., Penner, L., Schuster, S., Seidel, G. & Wandinger, K. P., 01.03.2023, in: Brain. 146, 3, S. 977-990 14 S.. Publikation: Beiträge in Fachzeitschriften › Zeitschriftenaufsätze › Forschung › Begutachtung ...
Safety and tolerability of a first in class chymase inhibitor in clinically stable patients with left-ventricular dysfunction ...
Chymase Therefore, auxilin 1 and auxilin 2 possess overlapping functions and may substitute for one another in sorting ...
Chymase These email address details are inconsistent with a youthful report that PE treatment caused p38 phosphorylation in ...
carboxypeptidase A3, cathepsin G and chymase 1 is associated with the extension of CAD and MI.. Methods: The 44 patients with ... Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after ... Cooperation between mast cell carboxypeptidase A and the chymase mouse mast cell protease 4 in the formation and degradation of ... serum concentrations of carboxypeptidase A3, cathepsin G and chymase 1 were also measured.. Results: Patients with single ...
... chymase, and heparin. By releasing these mediators, mast cells play a key role in generating protective acute inflammatory ...
Guinea pig chymase is leucine-specific: a novel example of functional plasticity in the chymase/granzyme family of serine ... To explore guinea pigs as models of chymase biology, we cloned and expressed the guinea pig ortholog of human chymase. In ... Unlike mouse, rat, and hamster alpha-chymases, guinea pig chymase lacks elastase-like preference for P1 Val or Ala. Partially ... Intriguingly, histamine levels were positively linked to tryptase and chymase activity, whereas tryptase and chymase activity ...
INVA8001 is designed as an oral, small molecule, highly selective and potent inhibitor of chymase, a key mediator of mast cells ...
EC 3.4.21.39 (chymase) inhibitor + EC 3.4.21.64 (peptidase K) inhibitor + EC 3.4.24.* (metalloendopeptidase) inhibitor + ...
Mast Cell Proteases Tryptase and Chymase Induce Migratory and Morphological Alterations in Bronchial Epithelial Cells. ...
2006). Expression of chymase-positive cells in gastric cancer and its correlation with the angiogenesis. J Surg Oncol 93, 36-42 ... 2006). Expression of chymase-positive cells in gastric cancer and its correlation with the angiogenesis. J Surg Oncol 93, 36-42 ...
The mediators that are immediately released include histamine, tryptase, chymase, kinins, and heparin. [9, 10] The mast cells ...
A chymase gene variant is associated with atherosclerosis in venous coronary artery bypass grafts. Coronary artery disease 2001 ...
Histamine, serotonin, heparin, neutral proteases (tryptase and chymase, carboxypeptidase, cathepsin G), major basic protein, ...
... varying in content of tryptase and chymase as well as in immunobiology. Mast cells are activated by numerous stimuli, including ...
  • Chymases (EC 3.4.21.39, mast cell protease 1, skeletal muscle protease, skin chymotryptic proteinase, mast cell serine proteinase, skeletal muscle protease) are a family of serine proteases found primarily in mast cells, though also present in basophil granulocytes (e.g. alpha chymase mcpt8). (wikipedia.org)
  • For example, chymases are released by connective tissue-type mast cells upon challenge with parasites and parasite antigens promoting an inflammatory response, and chymase mcp1 and mcp2 are used for marker for mast cell degranulation in parasite infection such as Nematode, Trichuris muris Chymases are also known to convert angiotensin I to angiotensin II and thus play a role in hypertension and atherosclerosis. (wikipedia.org)
  • INVA8001 is designed as an oral, small molecule, highly selective and potent inhibitor of chymase, a key mediator of mast cells driving inflammation, epithelial barrier damage and fibrosis. (iposcoop.com)
  • Mast Cell Proteases Tryptase and Chymase Induce Migratory and Morphological Alterations in Bronchial Epithelial Cells. (sigmaaldrich.com)
  • Mast cells continue their maturation and differentiation in peripheral tissue, developing into two well described subsets of cells, MC T and MC TC cells, varying in content of tryptase and chymase as well as in immunobiology. (imrpress.com)
  • Mast cells are cells that reside in the connective tissue and contain a large number of granules, rich in histamine, heparin, chymase, serotonin, and also cytokines. (bvsalud.org)
  • In the pregnant uterus, mast cell numbers increase in the myometrium and shift from both tryptase and chymase mast cells to the tryptase-only phenotype. (medscape.com)
  • General Description of Recombinant Canine CMA1 / Chymase 1 Protein. (enquirebio.com)
  • A DNA sequence encoding the Canis lupus familiaris (Dog) (Canis familiaris) CMA1 / Chymase 1, was expressed in the hosts and tags indicated. (enquirebio.com)
  • An inhibitor of renin or chymase abrogated A-II production in both cells. (aacrjournals.org)
  • In this diabetic mouse model, liver metastasis of CT26 cells was suppressed by anti-AT treatment with a chymase inhibitor, a renin inhibitor, and an AT-II receptor blocker. (aacrjournals.org)
  • carboxypeptidase A3, cathepsin G and chymase 1 is associated with the extension of CAD and MI. (viamedica.pl)
  • serum concentrations of carboxypeptidase A3, cathepsin G and chymase 1 were also measured. (viamedica.pl)
  • Renin acts on the substrate angiotensinogen to form angiotensin I. Angiotensin I undergoes transformation under the activity of several enzymes, including ACE and chymase, to angiotensin II. (cachefly.net)
  • A chymase gene variant is associated with atherosclerosis in venous coronary artery bypass grafts. (cdc.gov)
  • We found that the increased abundance of cleaved APOA1 peptides is likely a consequence of enzymatic degradation by metalloproteinases and chymase. (lu.se)
  • Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/reperfusion. (viamedica.pl)
  • Western Blot analysis of mouse lung cells using Chymase Polyclonal Antibody. (angenovo.no)
  • HT29 cells expressed AT-II type 1 receptor, chymase, and rennin, whereas CT26 cells did not express renin. (aacrjournals.org)
  • 2006). Expression of chymase-positive cells in gastric cancer and its correlation with the angiogenesis. (bio-rad-antibodies.com)
  • 9. The increase in tryptase- and chymase-positive mast cells is associated with partial inactivation of chymase and increase in protease inhibitors in basal cell carcinoma. (nih.gov)
  • 19. The relationship of tryptase- and chymase-positive mast cells to angiogenesis in stage I non-small cell lung cancer. (nih.gov)
  • Further study revealed that during anaphylaxis, mast cells release an enzyme called chymase, which interacts with a protein called TRPV1 on a subset of sensory nerve cells. (nih.gov)
  • Chymases are primarily found in the SECRETORY GRANULES of MAST CELLS and are released during mast cell degranulation. (bvsalud.org)
  • IL-6 alters cell morphology, and mast cells grown in the presence of IL-6 have more KIT high and Chymase high cells. (nih.gov)
  • 2. The combined action of mast cell chymase, tryptase and carboxypeptidase A3 protects against melanoma colonization of the lung. (nih.gov)
  • 8. Mast cell chymase and tryptase in abdominal aortic aneurysm formation. (nih.gov)
  • 10. Role of mast cell chymase and tryptase in the progression of atherosclerosis: study in 44 autopsied cases. (nih.gov)
  • 12. Tryptase and chymase are angiogenic in vivo in the chorioallantoic membrane assay. (nih.gov)
  • 13. Mast cell tryptase and chymase in the progress of cutaneous vasculitis. (nih.gov)
  • 16. Purification and characterization of mast cell tryptase and chymase from human tissues. (nih.gov)
  • 18. Direct effects of mast cell proteases, tryptase and chymase, on bronchial epithelial integrity proteins and anti-viral responses. (nih.gov)
  • 20. Altered immunohistochemical expression of mast cell tryptase and chymase in the pathogenesis of oral submucous fibrosis and malignant transformation of the overlying epithelium. (nih.gov)
  • Association between SNP rs1800875, serum chymase and immunoglobulin E levels in patients with coronary heart disease. (cdc.gov)
  • 1. The Role of Mast Cell Specific Chymases and Tryptases in Tumor Angiogenesis. (nih.gov)
  • Importantly, uniquely hypomethylated genes play roles in angiogenesis (e.g., chymase 1, tyrosine kinase nonreceptor 2, and possibly ephrin B2 and triple functional domain, PTPRF interacting) and invasion and metastasis, including those involved in the epithelial-mesenchymal transition (transcription factor 4, transforming growth factor beta receptor II, and ral guanine nucleotide dissociation stimulator). (nih.gov)
  • Chymase is the major angiotensin II (Ang II)-forming enzyme in cardiovascular tissue, with an important role in atrial remodeling. (nih.gov)